2015, Number 2
<< Back
Biotecnol Apl 2015; 32 (2)
Protective capacity of vaccine candidates against dengue virus type 2 based on the capsid protein and the oligodeoxynucleotide 39M
Marcos E, Gil L, Hermida L, Izquierdo A, Guillén G, Guzmán MG, Lazo L, Valdés I, Álvarez M, Suzarte E, Ramírez R, Castro J, Pérez Y, Cobas K, Silva JÁ, Romero Y, Cosme K, Brown E, Blanco A, Miranda J, Perera Y
Language: English
References: 11
Page: 1501-1503
PDF size: 228.88 Kb.
ABSTRACT
Vaccine formulations of the chimeric DIIIC-2 protein with different ODNs displaying adjuvant capacity were tested in mice against dengue virus serotype 2. DIIIC-2 comprises domain III from the envelope protein fused to the N-terminal region of the capsid protein. One of the ODNs, named ODN 39M, combines CpG motifs described as immunostimulatory active in mice, monkeys and human cells. The ODN sequence determined the immune response pattern generated, since ODN 39M was the only ODN inducing a Th1 response similar to that induced by the viral infection in mice. Hence, ODN 39M was aggregated with either the capsid protein of dengue-2 (C-2) or the DIIIC-2 protein, and both formulations were adjuvanted in alum. Upon administration in two mice models and in non-human primates, both formulations induced protection after the viral challenge. This was the first demonstration of the protective capacity induced by the vaccine formulation 39M-DIIIC-2 in non-human primates and in transgenic mouse models which develop dengue-like clinical symptoms. Moreover, viremia levels were reduced in non-human primates with the 39M-C-2 formulation. This was the first evidence ever on the induction of a functional immune response against dengue virus by vaccination in non-human primates, regardless the presence of neutralizing antibodies. Moreover, this was the first work describing protection in monkeys with a formulation that is suitable for human use and combines recombinant proteins from dengue virus with alum. This research granted the 2014 Award of the Cuban National Academy of Sciences.
REFERENCES
Valdes I, Bernardo L, Gil L, Pavon A, Lazo L, Lopez C, et al. A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology 2009;394:249-58.
Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/ beta in plasmacytoid dendritic cells. Eur J Immunol 2001;31:2154-63.
Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. J Immunol 2001;166:2372-7.
Schellack C, Prinz K, Egyed A, Fritz JH, Wittmann B, Ginzler M, et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006;24:5461-5472.
Gil L, Marcos E, Izquierdo A, Lazo L, Valdes I, Ambala P, et al. The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV- 2. Immunol Cell Biol. 2015;93(1):57-66.
Gil L, Izquierdo A, Lazo L, Valdes I, Ambala P, Ochola L, et al. Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys. Virology. 2014;456-457:70-6.
Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006;24:3165-71.
Bernardo L, Izquierdo A, Alvarez M, Rosario D, Prado I, Lopez C, et al. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res 2008;80:194-9.
Simmons M, Porter KR, Hayes CG, Vaughn DW, Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 2006;80:9577- 9585.
Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, et al. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 2010;28:2705-15.
Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLAlinked protective role for CD8+ T cells. Proc Natl Acad Sci USA. 2013;110:E2046-53.